metastatic castration resistant prostate cancer (mCRPC) research hub

Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)

This study is looking at how best to give two common treatments, Radium-223 and Docetaxel, for prostate cancer that has spread to the bones. It compares different ways of giving these treatments to see which works best for improving quality of life and managing pain.